ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 777,76
0,46%
Dow Jones
42 175,11
0,00%
DAX
19 442,40
1,16%
Brent Oil
70,955
0,01%
Bitcoin
65 600,32
0,65%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Vertex Pharmaceuticals Inc (VRTX)

  7. Vertex Pharmaceuticals Inc (VRTX) Actualités

VRTX

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:VRTX
DateHeureSourceTitreSymboleSociété
26/09/202415h00PR Newswire (Canada)Vertex annonce l'acceptation par Santé Canada de la soumission de drogue nouvelle pour l'association vanzacaftor/tézacaftor/deutivacaftor, un traitement d'association triple de nouvelle génération pour la fibrose kystiqueNASDAQ:VRTXVertex Pharmaceuticals Inc
26/09/202415h00PR Newswire (Canada)Vertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic FibrosisNASDAQ:VRTXVertex Pharmaceuticals Inc
26/09/202413h07Business WireVertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis ConferenceNASDAQ:VRTXVertex Pharmaceuticals Inc
25/09/202421h51PR Newswire (Canada)Santé Canada accorde l'autorisation de mise sur le marché de la première thérapie d'édition génomique CRISPR/Cas9, CASGEVY® (exagamglogène autotemcel), pour le traitement de l'anémie falciforme et de la bêta-thalassémie dépendante des transfusiNASDAQ:VRTXVertex Pharmaceuticals Inc
25/09/202421h50PR Newswire (Canada)Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaNASDAQ:VRTXVertex Pharmaceuticals Inc
04/09/202422h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
30/08/202422h47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
22/08/202414h00Business WireVertex to Participate in Upcoming September Investor ConferencesNASDAQ:VRTXVertex Pharmaceuticals Inc
16/08/202422h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
08/08/202401h12Business WireVertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in EnglandNASDAQ:VRTXVertex Pharmaceuticals Inc
02/08/202422h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRTXVertex Pharmaceuticals Inc
01/08/202422h01Business WireVertex Reports Second Quarter 2024 Financial ResultsNASDAQ:VRTXVertex Pharmaceuticals Inc
30/07/202419h10Business WireVertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute PainNASDAQ:VRTXVertex Pharmaceuticals Inc
15/07/202415h00PR Newswire (Canada)Santé Canada autorise la commercialisation de TRIKAFTA(MD) (éléxacaftor/tézacaftor/ivacaftor et ivacaftor) chez les personnes atteintes de fibrose kystique âgées de 2 ans et plus présentant certaines mutations raresNASDAQ:VRTXVertex Pharmaceuticals Inc
15/07/202415h00PR Newswire (Canada)Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare MutationsNASDAQ:VRTXVertex Pharmaceuticals Inc
02/07/202414h33Business WireVertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic FibrosisNASDAQ:VRTXVertex Pharmaceuticals Inc
01/07/202422h05Business WireVertex to Announce Second Quarter 2024 Financial Results on August 1NASDAQ:VRTXVertex Pharmaceuticals Inc
21/06/202421h45Business WireVertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific SessionsNASDAQ:VRTXVertex Pharmaceuticals Inc
20/06/202413h15Business WireVertex Announces Extended Long-Term Reimbursement Agreement with NHS England for Access to Cystic Fibrosis Medicines KAFTRIO®, SYMKEVI® and ORKAMBI®NASDAQ:VRTXVertex Pharmaceuticals Inc
14/06/202409h03Business WireVertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) CongressNASDAQ:VRTXVertex Pharmaceuticals Inc
07/06/202418h00Business WireVertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®NASDAQ:VRTXVertex Pharmaceuticals Inc
04/06/202415h10IH Market NewsEconomic Worries May Lead To Weakness On Wall StreetNASDAQ:VRTXVertex Pharmaceuticals Inc
22/05/202422h05Business WireVertex to Participate in Upcoming June Investor ConferencesNASDAQ:VRTXVertex Pharmaceuticals Inc
20/05/202414h25Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:VRTXVertex Pharmaceuticals Inc
17/05/202422h16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
15/05/202416h30Business WireJennifer Schneider Elected to Vertex Board of DirectorsNASDAQ:VRTXVertex Pharmaceuticals Inc
07/05/202413h46IH Market NewsDisney Slashes Streaming Losses, UBS shoots up 9% as profit triples expectations, and More in EarningsNASDAQ:VRTXVertex Pharmaceuticals Inc
06/05/202422h01Business WireVertex Reports First Quarter 2024 Financial ResultsNASDAQ:VRTXVertex Pharmaceuticals Inc
06/05/202414h09IH Market NewsIndex Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices RiseNASDAQ:VRTXVertex Pharmaceuticals Inc
26/04/202417h43Business WireVertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and OlderNASDAQ:VRTXVertex Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:VRTX

Dernières Valeurs Consultées

NYSE
KTX
Xerox Cap Corts
NYSE
EXCU
Exelon Corp.
TG
NV4
Cellectar Biosciences
TG
4LN2
Capricor Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés